长春高新：控股子公司两款药品新纳入国家医保目

Core Insights - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, has two products included in the National Medical Insurance Directory for 2025, which may enhance their market potential and accessibility [1][2] Group 1: Product Overview - Jinsai Zeng (known as Jin Pei Growth Hormone Injection) is a long-acting growth hormone approved in January 2014, with indications for various growth disorders in children and is the only long-acting growth hormone in China with over 150,000 real-world data validating its long-term efficacy and safety [1] - Meishiya (known as Acetate Medroxyprogesterone Oral Suspension) is developed by Bosheng Pharmaceutical and has been authorized for exclusive distribution by Jinsai Pharmaceutical in several regions, with indications for treating anorexia in patients with acquired immune deficiency syndrome and cachexia in cancer patients [2] Group 2: Clinical Development - Jinsai Zeng is currently undergoing Phase III clinical trials for treating adult growth hormone deficiency and Phase II trials for addressing growth retardation in children born small for gestational age, indicating ongoing efforts to expand its therapeutic applications [1] - Meishiya utilizes innovative nanotechnology to improve treatment efficacy and speed for cachexia patients, addressing a significant clinical gap, and is recommended in clinical guidelines for cancer-related anorexia-cachexia syndrome [2]